On the other hand, inhibiting PPARγ prevents proliferation of human colon cancer HT-29 cells, as evidenced by challenge with cyclic phosphatidic acid (cPA), a structural analog of lysophosphatidic acid (LPA), and a specific, high-affinity PPARγ antagonist [30]. Here, PPARG is linked to malignant colon neoplasm.